Veru Inc. (NASDAQ:VERU) Stake Boosted by State Street Corp

State Street Corp raised its position in shares of Veru Inc. (NASDAQ:VERU) by 4.3% in the third quarter, Holdings Channel.com reports. The institutional investor owned 2,072,065 shares of the company’s stock after buying an additional 84,483 shares during the period. State Street Corp’s holdings in Veru were worth $1,593,000 at the end of the most recent quarter.

Other hedge funds and other institutional investors also recently made changes to their positions in the company. Gladstone Institutional Advisory LLC lifted its position in shares of Veru by 34.2% in the 3rd quarter. Gladstone Institutional Advisory LLC now owns 56,876 shares of the company’s stock valued at $44,000 after acquiring an additional 14,500 shares in the last quarter. SG Americas Securities LLC lifted its holdings in shares of Veru by 185.9% in the third quarter. SG Americas Securities LLC now owns 66,128 shares of the company’s stock valued at $51,000 after purchasing an additional 42,997 shares in the last quarter. PVG Asset Management Corp acquired a new stake in shares of Veru in the second quarter worth $474,000. Perceptive Advisors LLC grew its holdings in shares of Veru by 26.5% during the second quarter. Perceptive Advisors LLC now owns 7,063,277 shares of the company’s stock valued at $5,942,000 after buying an additional 1,478,578 shares in the last quarter. Finally, Squarepoint Ops LLC acquired a new position in Veru during the second quarter valued at $161,000. 47.16% of the stock is currently owned by institutional investors and hedge funds.

Veru Trading Up 2.4 %

Shares of VERU stock opened at $0.65 on Thursday. The stock has a 50 day moving average of $0.70 and a two-hundred day moving average of $0.80. The company has a market capitalization of $95.22 million, a P/E ratio of -1.36 and a beta of -0.50. Veru Inc. has a 12 month low of $0.36 and a 12 month high of $1.92.

Veru (NASDAQ:VERU) last announced its quarterly earnings results on Monday, December 16th. The company reported ($0.06) EPS for the quarter, topping analysts’ consensus estimates of ($0.07) by $0.01. Veru had a negative net margin of 376.38% and a negative return on equity of 115.99%. Sell-side analysts predict that Veru Inc. will post -0.3 earnings per share for the current fiscal year.

Wall Street Analyst Weigh In

A number of equities analysts have recently weighed in on VERU shares. HC Wainwright reiterated a “buy” rating and issued a $3.00 target price on shares of Veru in a report on Friday, December 20th. Oppenheimer reaffirmed an “outperform” rating and set a $5.00 price objective on shares of Veru in a research report on Tuesday, November 5th.

Veru Profile

Veru Inc, a late clinical stage biopharmaceutical company, focuses on developing medicines for treatment of metabolic diseases, oncology, and acute respiratory distress syndrome (ARDS). Its marketed products comprise FC2 female condom for the dual protection against unplanned pregnancy and the transmission of sexually transmitted infections.